organisms, and their corresponding therapeutic potential is of growing interest to academics and industrial researchers alike. However, applications of these proteins are limited due to their low stability in vivo and in vitro. Here we tackle this problem using a generalizable computer-assisted protein engineering strategy to create a unique modified FGF2 with nine mutations displaying unprecedented stability and uncompromised biological function.
Introduction
The structurally related and highly conserved polypeptides from the family of FGFs are involved in a number of physiological processes in diverse animal species including humans.
There has been a considerable effort in investigating members of the FGF family for applications in pharmacy and bioengineering 1 . Specifically, human FGF2 serves as a pleiotropic regulator of proliferation, differentiation, migration, and survival in a variety of cell types and has been studied as a promising agent in treatment of cardiovascular diseases 2 , cancer 3 and mood disorders 4 . It has also been shown to have efficacy in ulcer, wound 5, 6 and epithelium healing 7 and is being routinely used as an essential component of cultivation media for human embryonic stem cells 8 .
The long-term maintenance of growth factors in the tissue or media is desirable for protein therapies and stem cell culturing, but is hindered by low thermal stability of the molecules and their limited half-life 1, 9, 10 . Stability of FGFs was shown to be enhanced by coadministration with heparin 11 , conjugation to heparin-mimicking polymers 12 , encapsulation in microspheres 13 , or fusion with proteoglycan 14 . However, these strategies possess various limitations. They might significantly affect protein activity and are of prime concern from both safety and economic standpoints. Development of soluble, heparin-independent FGF analogues with improved stability is clearly needed for broader use of these interesting molecules 1 .
Protein engineering is a powerful approach for protein stabilization 15, 16 . Stabilization by engineering has been previously applied to highly unstable FGF1 and resulted in improved mitogenic activity half-life by introducing stabilizing mutations at N and C terminus β-strand interactions of a β-barrel architecture. 17, 18 Triple 19 and quintuple 20 FGF2 mutants with improved stability and up to 10-fold prolonged activity in cell culture were recently prepared by aligning protein sequences of wild-type FGF2 with previously reported stabilized FGF1 mutants or by employing and combining individual stabilizing mutations published elsewhere.
Nevertheless, the true potential of state-of-the-art protein engineering strategies has not yet been exploited in the design of stable FGFs. Here, we describe engineering of a unique ninepoint mutant of low molecular weight isoform FGF2 with melting temperature (Tm) increased by 19°C and in vitro functional half-life at 37°C improved from 10 hours to more than 20 days. This was achieved by following a computer-assisted engineering strategy combining energybased and evolution-based analyses 21 with focused directed evolution ( Fig. 1 ). We demonstrate that the developed molecule holds a great promise both for in vitro and in vivo applications.
Results and discussion
Using our platform, we proposed 12 single point mutations (R31L, R31W, V52T, H59F, C78Y, N80G, L92Y, C96Y, S109E, R118W, T121K, and V125L) and 7 positions for randomization (E54, C78, R90, S94, C96, T121, and S152) to stabilize FGF2 by computationally searching for mutations that would minimize the Gibbs free energy of the native state combined with a back-to-consensus analysis ( Fig. 1 step I, Supplementary Figs. 1-2 ). Three out of twelve most stabilizing substitutions were identified by the phylogenetic approach 22 and nine mutations were predicted from energetics using FoldX 23 and Rosetta ddg monomer 24 (Supplementary Tables 1 and 2 ). Seven positions with the highest number of potentially stabilizing mutations as defined by the difference in their free energy (G) < -1 kcal.mol -1 were considered for randomization in order to look for further beneficial substitutions overlooked by the rational approach (Supplementary Table 2 ). Functionally relevant positions, namely those residues within heparin or receptor binding sites, were excluded from the designs to avoid mutations compromising activity. Initially, 12 computationally designed point mutants (FGF2-G1A) were constructed and tested leading to 7 stabilizing substitutions at 6 different positions with Tm between 0.9 and 3.7°C. Six selected substitutions were recombined giving rise to the second generation mutant FGF2-G2 with Tm of 15°C.
Subsequently, 420 clones from 7 focused site-saturation mutagenesis libraries were screened for enhanced thermostability and retained biological activity (FGF2-G1B), revealing 14 beneficial substitutions at 5 randomized positions with Tm between 0.3 and 2.9°C. Guided by computational predictions, 5 substitutions from rational design were combined with 4 mutations from semi-rational design providing the third generation protein FGF2-G3 with Tm of 19°C.
For the purpose of in vitro mutagenesis ( Fig. 1 steps II and IV), the gene encoding wildtype FGF2 was subcloned into vector pET28b with cleavable N-terminal His tag giving rise to the recombinant variant designated FGF2-G0 ( Supplementary Fig. 2 ). The numbering of mutations used herein corresponds to the original sequence of wild-type FGF2 ( Supplementary   Fig. 2c ). The genes of 12 rationally designed single-point mutants representing the first generation of engineered FGF2 (FGF2-G1A) were synthesized. Twelve mutants were produced in soluble form in Escherichia coli BL21(DE3) in quantities similar to that of FGF2-G0 (± 5% of the total soluble protein) and purified to homogeneity using affinity chromatography.
Biophysical characterization ( Fig. 1 step II) verified proper folding of all 12 mutants and improved Tm for 7 out of 12 constructed variants (Supplementary Table 3 ). Six beneficial mutations (R31L, V52T, H59F, L92Y, C96Y, and S109E) were re-combined in the cumulative mutant FGF2-G2 ( Fig. 1 step III), which was obtained at a yield of 20 mg.L -1 . The experimental Tm of properly folded FGF2-G2 (68.0 ± 0.2°C) was about 14.5°C higher than Tm of FGF2-G0 (53.5 ± 0.5°C). This value corresponds well with the theoretical sum of contributions of individual substitutions, suggesting strictly additive stabilizing effect of mutations in FGF2- Table 4 ). 6 In the next step, 7 computationally pre-selected positions in FGF2-G0 were randomized ( Fig. 1 step IV) using fixed oligo technology, which reduced the screening effort needed to only 60 clones per library to obtain full coverage. Crude extracts of individual E. coli clones were prepared in microtiter plates and used to test simultaneously for biological activity and stability of FGF2 mutants in growth arrest assay with rat chondrosarcoma cells ( Supplementary   Fig. 3 ). Altogether, 33 new FGF2-G1B mutants were identified during the screening and successfully produced in E. coli to the levels similar to that of FGF2-G0. Thermal shift assays with purified proteins revealed 14 stabilizing amino acid substitutions in 5 out of 7 randomized positions ( Supplementary Table 5 ). Mutations showing an improved thermostability of at least 1°C (E54D, S94I, C96N, and T121P) were computationally merged with existing mutations in FGF2-G2 (R31L, V52T, H59F, L92Y, C96Y, and S109E, while replacing C96Y by C96N) leading to the third generation variant FGF2-G3 ( Fig. 1 steps V and VI and Fig. 2a ). Both FGF2-G2 and FGF2-G3 retained most of their original activity for 20 days of experiment, while FGF2-G0 lost half of its activity within initial 10 hours as determined by densitometric analysis of the corresponding Western blots ( Supplementary Fig. 8 ). Purified FGF2-G3, obtained with the yield of 11 mg.L -1 , was initially characterized in vitro using a wide spectrum of biophysical methods ( Fig. 1 step VII). The properly folded mutant ( Fig. 2b ) exhibited a Tm of 72.2 ± 0.1°C and Tm of 18.7°C compared with FGF2-G0, showing again the additive stabilizing effect of all new mutations, precisely predicted by the free energy calculation (theoretical Tm of 19.2°C). In terms of structural integrity at elevated temperatures, FGF2-G3 clearly outperformed both FGF2-G0 and FGF2-G2, showing the halflife of its secondary structure of >24 h at 50°C and 1.6 h at 70°C ( Fig. 2c and Supplementary   Fig. 4 ). Fitting the data to a two-step unfolding mechanism suggested that gained stability was due to an increase in the Gibbs activation energy of the first unfolding step, which is in excellent agreement with our overall computational strategy of lowering the energy of the native state ( Fig. 2d , Supplementary Results, Supplementary Table 6 and Figs 5-7).
G2 (Supplementary
Biological assays confirmed the enhanced stability of engineered growth factors translated into their prolonged activity in vitro and in vivo ( Fig. 1 step VII) . Specifically, while the activity of FGF2-G0 in an ERK1/2 assay with human embryonic stem cells dropped to 50 % within initial 10 ± 2 hours of pre-incubation in conditioned medium at 37°C (Fig 2e and Supplementary Fig. 8 ), which is in good agreement with data obtained previously by different techniques 1,25 , G2 and G3 mutants retained most of their activity for the full length of the study period (20 days) at the physiological temperature. In the second assay, the human embryonic stem cells were propagated in medium conditioned with each of the tested FGF2 variants with no additional supplementation, and the cell numbers and morphology were recorded for five consecutive passages ( Fig. 2f and Supplementary Fig. 9 ). While conditioned medium prepared with FGF2-G0 caused significant growth retardation, the cells incubated in the medium with either G2 or G3 mutant gave rise to monolayers, suggesting that repeated supplementation of the conditioned medium is not required with these proteins. Immunostaining for Oct-4 and Nanog after five passages on Matrigel proved that all tested FGF2 variants support expression of pluripotency markers ( Supplementary Fig. 10 ).
The biological activity of the stabilized variant was confirmed in vivo by injecting either FGF2-G0 or FGF2-G3, sorbed into a non-biodegradable hydrogel, into the shaved dorsal skin of telogenic C57BL/6 mice ( Supplementary Fig. 11 and 12 ). It is known that growth factors from FGF family have positive effect on hair growth and hair follicle stimulation. 26 We evaluated the degree of black pigmentation and hair growth photometrically by observing the skin color for 20 days. In 2 weeks, both FGF2 induced black coloration in the shaved skin with remarkably stronger hair growth induction in group injected with thermostable FGF2 ( Fig. 3a , Supplementary Fig. 12 ). The control group with empty hydrogel showed significant retardation in transition from telogen to anagen stage as seen on skin coloration. The hair length of plucked hair in the proximity of injected site confirmed that thermostable FGF2 stimulated growth of hairs more significantly comparing to FGF2-G0 and the control group with no FGF2 applied In summary, we constructed a hyperstable nine-point mutant FGF2-G3 using a hybrid computational engineering strategy and focused directed evolution by constructing only 14 mutants and testing only 420 clones. The FGF2-G3 shows a 19°C increase in melting temperature and greater than 48-fold improved half-life at 37°C, representing the most thermostable FGF2 with fully preserved biological activity known to date. Our hyperstable FGF2 supports the undifferentiated growth of human embryonic stem cells, induces the appropriate downstream signaling cascade, and stimulates hair growth in mouse model, demonstrating that its biological activity towards highly sensitive cells remained unmodified. 11 We anticipate this construct will be directly applicable to stem cell culturing 13 , and will find broad use in clinical medicine 1, 12 , cosmetics 26 , and dietary supplements. The successful demonstration of rapid protein stabilization highlights the power of our rational protein engineering strategy and should encourage wider use of the described workflow for stabilizing growth factors and other protein therapeutics that are currently being tested for use in cancer treatment, regenerative medicine, or a number of metabolism-associated disorders 1 .
Materials and methods

Prediction of stabilizing effect of single-point mutations by evolution-based approach
Multiple sequence alignment and evolutionary conservation analysis. The FGF2 isoform 3 protein sequence (UniProt identifier: P09038-2) was used as a query for PSI-BLAST 28 search against nr database of NCBI. PSI-BLAST was performed with the E-value thresholds of 10 -1 for the initial BLAST search and the threshold of 10 -5 for inclusion of the sequence in the position specific matrix. Sequences collected after 3 iterations of PSI-BLAST were clustered by CD-HIT 29 at the 90% identity threshold. Resulting dataset of 554 sequences was clustered with CLANS 30 using default parameters and varying P-value thresholds.
Sequences clustered together with FGF2 at the P-value of 10 -30 were extracted and aligned with the MUSCLE program 31 . The alignment was refined manually in BioEdit 32 . All incomplete or diverged sequences were removed. The final alignment comprising 238 sequences was used to estimate the level of conservation of individual sites within the FGF2 related proteins. Relative evolutionary rates for individual positions were calculated by the Rate4Site v2.01 program 33 using the empirical Bayesian method 34 and WAG model of evolution 35 . The evolutionary rates were then converted to the ConSurf conservation scale 36 .
Selection of individual mutations. The multiple sequence alignment comprising 238 FGF2 protein sequences was used as an input for back-to-consensus analysis using the simple consensus approach. The analysis was performed using the consensus cut-off of 0.5, meaning that a given residue must be present at a given position in at least 50% of all analysed sequences to be assigned as the consensus residue. Stability effects of all possible single-point mutations in FGF2 protein were estimated by free energy calculations (see following section for the calculation details). Only mutations with average Gibbs free energy (ΔΔG) ≤ 1 kcal.mol -1 predicted by both FoldX 22 and Rosetta 23 were considered as hot-spots for FGF2 stabilization.
Functionally important sites of FGF2 were excluded as potentially deleterious mutations for biological function. Results of the back-to-consensus analysis are summarized in Supplementary Table S1 . The numbering corresponds to the sequence of wild-type human FGF2 ( Supplementary Fig. 2c ). Ten mutations were excluded based on the high value of predicted ΔΔG or its high uncertainty of the prediction, and three mutations were discarded from the design due to their location at functionally important positions for the heparin binding.
Four single-point mutations V52T, N80G, L92Y and S109E passed all criteria and were selected for experimental construction and characterization.
Prediction of stabilizing effect of single-point mutations by energy-based approach, selection of positions for randomization
Available structures of FGF2 with resolution higher than 2.20 Å (PDB-ID codes:
1BFG, 4FGF, 2FGF, 1BAS, 1BFB, 1BFC, 1BFF, 1EV2, 1FGA) were downloaded from the RCSB Protein Data Bank 37 . The structures were visualized in PyMOL molecular graphics system v 1.7.7.4 (Schrödinger LLC, USA) and prepared for analyses by removing ligands and water molecules. Chain A was chosen in the case of multiple chain structure. Missing atoms in side chains were added by <RepairPDB> module of FoldX 22 . Three rounds of optimization with increasing weight on the repulsive term (--ramp_repulsive true) were applied. The minimum energies from 20 iterations were used as the final parameters describing the stability effects of single -point mutations.
Selection of individual mutations. Mutations predicted as stabilizing by either FoldX or
Rosetta tool (ΔΔG < -1.0 kcal.mol -1 ) and not significantly constrained during evolution (Consurf conservation score < 8) were selected for further analysis. In this way, the potentially stabilizing mutations with only a limited influence on functional regions, e.g., heparin binding residues, were identified. Residues forming the FGF2/FGFR1 interface (PDB-ID code 1CVS) and FGF2/FGFR2 interface (PDB-ID code 1EV2) were identified using the PISA server 38 and were discarded from the selection. Nine single-point substitutions were selected for experimental construction and characterization: R31W, R31L, H59F, C78Y, L92Y, C96Y, R118W, T121K and V125L (Supplementary Table 2 ). Interestingly, the L92Y mutation was identified also previously by evolutionary-based approach. The numbering of these mutants corresponds to the sequence of wild-type human FGF2 ( Supplementary Fig. 2c ). 15 Selection of positions for saturation mutagenesis. Positions for saturation mutagenesis that should reveal additional stabilizing mutations were proposed using Rosetta calculations.
Every protein position was saturated by all twenty proteinogenic amino acids and number of stabilizing mutations (ΔΔG < -1.0 kcal.mol -1 ) was identified for individual positions. Positions with conservations score > 7 or situated on the functional regions were discarded. Seven positions with the highest number (> 3) of stabilizing mutations (E54, C78, R90, S94, C96, T121, and S152) were selected for saturation mutagenesis (Supplementary Table 2 ). Positions 31 and 59 were discarded from selection because significant improvement in thermostability (ΔTm=4°C and 3°C, respectively) was verified experimentally for the mutations R31L and H59F ( Supplementary Table 3 ). Therefore, the probability of further considerable improvement was negligible.
Construction, production and characterization of single point FGF2-G1A variants
Twelve FGF2-G1A variants R31W, R31L, V52T, H59F, C78Y, N80G, L92Y, C96Y, S109E, R118W, T121K and V125L were commercially synthesized (GeneArt/Life Technologies, Germany) and subcloned in the NdeI and XhoI sites of pET28b-His-thrombin downstream inducible T7 promotor. E.coli BL21(DE3) cells were transformed with expression vectors, plated on agar plates with kanamycin (50 μg.ml -1 ) and grown overnight at 37°C. Single colonies were used to inoculate 10 ml of LB medium with kanamycin and cells were grown Differential scanning calorimetry and circular dichroism spectroscopy. The thermostability of FGF2-G1 mutants was determined by differential scanning calorimetry (DSC) assay. Thermal unfolding of 1.0 mg.ml -1 protein solutions in 50 mM phosphate buffer (pH 7.5) with 750 mM sodium chloride was followed by monitoring the heat capacity using the VP-capillary DSC system (GE Healthcare, USA). The measurements were performed at the temperatures from 20 to 80°C at 1°C.min -1 heating rate. Tm was evaluated as the top of the Gaussian curve after manual setting of the baseline. Proper folding of all mutants was verified by circular dichroism (CD) spectroscopy. CD spectra of mutants dialyzed in 50 mM phosphate buffer pH 7.5 and diluted to the concentration of 0.2 mg.ml -1 were recorded at 20°C using a spectropolarimeter Chirascan (Applied Photophysics, United Kingdom) equipped with a Peltier thermostat. Data were collected from 200 to 260 nm, at 100 nm.min -1 , 1 s response time and 2 nm bandwidth using a 0.1 cm-quartz cuvette. Each spectrum is the average of five individual scans and is corrected for absorbance caused by the buffer. Collected CD data were expressed in terms of the mean residue ellipticity. Thermal unfolding was followed by monitoring the ellipticity at 232 nm over the temperature range from 20 to 80°C at a heating rate 1°C.min -1 . Recorded thermal denaturation curves of FGF2 variants were normalized to represent signal changes between approximately 0 and 1 and fitted to sigmoidal curves. The melting temperatures were evaluated from the collected data as a midpoint of the normalized thermal transition.
Free energy calculations, construction and thermostability analysis of FGF2-G2 mutant
All mutations improving the melting temperature by at least 0.5°C were selected for in silico analysis using Rosetta ddg monomer application 23 as described earlier. In the case of two stabilizing mutations on the same position, the mutation with the larger effect was chosen.
Selected mutations were then tested for potential antagonistic effect. The additivity of stabilizing mutations was evaluated by predicting the stability of variants with all pairs of stabilizing single-point mutations ( Supplementary Table 4 ). Mutation pairs for which the respective double-point mutants showed lower stability in the comparison with the sum of both single-point mutants taken separately would be considered as antagonistic. However, none of the double-point mutants had the difference > 1 kcal.mol -1 suggesting the absence of any significant antagonistic effects among the selected mutations. All mutations improving Tm by at least 0.5°C (R31L, V52T, H59F, L92Y, C96Y and S109E) were combined into 6-point mutant designated FGF2-G2. The gene of multiple-point mutant was commercially synthesized (GeneArt/Life Technologies, Germany), subcloned in the NdeI and XhoI sites of pET28b-His-Thrombin and expressed in E. coli BL21(DE3) cells as described before. DSC was used to characterize protein thermal stability of protein purified by affinity chromatography. DSC data collection was performed over a temperature range of 20°C-100°C. Cells were treated with preincubated FGF2 at a final concentration of 20 ng.ml -1 for 4 days.
Construction and screening of focused site-saturation mutagenesis libraries
Cells were washed with PBS, fixed with 4% paraformaldehyde, washed again and stained with 0.025% crystal violet for 1 hour. Coloured cells were 3 times washed with distilled water.
Colour from cells was dissolved in 33% acetic acid. Absorbance was measured at 570 nm ( Supplementary Fig. 3 ). The more stable variant of FGF2 was present in added crude extract, the more evident was the growth inhibition. Samples causing more significant growth inhibition than samples containing FGF2-G0 were considered as positive hits. E. coli clones containing FGF2 candidates were refreshed from glycerol replica plates. For each of positive hits, four wells with LB medium in fresh 1 ml 96-well PP microtiter plate were inoculated and the whole screening procedure was repeated. For each of FGF2 candidates verified in second round of screening, 10 ml of LB medium with kanamycin was inoculated with corresponding E. coli clone from glycerol replica plate and the cells were grown overnight at 37°C with shaking. The overnight culture was used for isolation of plasmid DNA using GeneJET Plasmid Miniprep kit (Thermo Fisher Scientific, USA) and fgf2-G1B genes were commercially sequenced by Sanger method (GATC Biotech, Germany). Resulting sequences were aligned with nucleotide sequence of FGF2-G0 using BioEdit32 for determination of newly inserted mutations. Supplementary Table 5 ).
Small scale production and characterization of selected FGF2-G1B mutants
Free energy calculations, construction and purification of FGF2-G3 mutant
All mutations from screening improving the melting temperature by at least 1°C (E54D, S94I, C96N, and T121P) were selected for in silico analysis using Rosetta ddg monomer application 23 as described earlier. All double-point mutant combinations of newly identified mutations with existing mutations from stable variant FGF2-G2 (R31L, V52T, H59F, L92Y, C96Y, and S109E) were constructed in silico to predict potential additivity of these individual mutations (data not shown). Predicted ΔΔG was compared with the sum of ΔΔG of individual mutations but none of the double point mutants had the difference > 1 kcal.mol -1 again suggesting the absence of any antagonistic effects among selected mutations. Consequently, 9point mutant FGF2-G3 was designed and constructed combining 4 most stabilizing substitutions obtained from screening with 5 substitutions from FGF2-G2. In FGF2-G3 mutant, the substitution C96N was prioritized over C96Y due to its higher individual stabilizing effect verified experimentally. Predicted improvement in Tm for this new variant was 19.2°C. The gene of multiple-point mutant was commercially synthesized (GeneArt/Life Technologies, Germany), subcloned in the NdeI and XhoI sites of pET28b-His-Thrombin and expressed in E. coli BL21(DE3) cells as described before.
Characterization of biophysical properties of FGF2-G3 and its comparison with FGF2-G0 and FGF-G2 variants.
DSC was used to characterize protein thermal stability of protein purified by affinity chromatography. DSC data collection was performed over a temperature range of 20°C-100°C.
Proper folding of mutant was verified by CD spectroscopy as described earlier.
Circular dichroism spectroscopy. The structural integrity of FGF2-G0, FGF2-G2 and FGF2-G3 proteins was followed by monitoring the ellipticity over the wavelength range of 200 23 to 260 nm at the temperature 37, 50, 65 and 70°C for 24 h. Data were recorded in 2 minute intervals with 1 nm bandwidth using a 0.1 cm quartz cuvette containing the protein. Recorded denaturation curves (either single exponential, double exponential or exponential linear combination function) of tested FGF2 variants were globally fitted to exponential decay curves using OriginPro8 software (OriginLab, USA). Half-life of FGF2 secondary structure (t1/2 defined as a time required to reduce the initial value of ellipticity, as a measure of protein secondary structure, to ½ of the original value) was evaluated from the collected data as a decay constant (τ) using the equation:
where λ is exponential decay constant. The t1/2 was evaluated from the data collected at 227 nm, where all spectra showed the ellipticity maxima ( Supplementary Fig. 4 ). The maximum time of measurement of 24 h was limited by the capacity of the bomb with compressed nitrogen used in the CD spectroscopy protocol. The values of t1/2 for FGF2-G0 at 65 and 70 °C were not determined because the proteins were denatured immediately at the beginning of the measurement.
Fluorescence spectroscopy. Local conformational changes during thermal unfolding of Although the datasets of the wild type and the G2 mutant were fitted reasonably well with just a three-step irreversible model, the G3 model had to include one additional reversible pretransitional step to fit all the data sets perfectly, mainly due to the DSC data and ratiometric data from DSF. Nonetheless, the effect of this step is much less pronounced than the subsequent irreversible steps of unfolding in all the datasets. The estimated values of the main parameters of the unfolding mechanism are given in Supplementary Table 6 .
pH profile. Britton-Robinson buffers of different pHs (5, 6, 7, 7.5, 8, 9, 10 and 11) were used for determination of pH stability profile for the FGF2 variants. 5 µL sample aliquot was mixed with 95 µL of BR buffer of appropriate pH, thoroughly vortexed and incubated for 3 h at 4 °C. Next standard grade capillary was filled with a mixture by capillary forces and put into the Prometheus NT.48. Samples were scanned from 30 to 90 °C at 1°C.min -1 scan rate.
Characterization of biological properties of FGF2-G3 and its comparison with G0 and G2 variants
The authors herein declare that all following experiments conducted on animals or human cells were carried out in accordance with relevant guidelines and regulations. All Fig. 8 ). Data points were analysed using single exponential decay equation: ng.ml -1 FGF2 is usually conditioned by mitotically inactivated mEF for 5-7 days and then supplemented by 10 ng.ml -1 of FGF2 to restore growth factor concentration due to its degradation. In our experiments, to test the long-term thermostability of FGF2, the CM was prepared out of medium containing 10 ng.ml -1 of FGF2 with no supplementation afterwards.
Proliferation assays. The hESC were plated into 24-well plates and propagated in presence of each of the tested FGF2 for five passages and counted every three days after plating using Burker chamber. Alternatively, cells were plated into 94-well plates and cultured in the presence of various FGF2 for 6 days. Cells were then fixed in 4% paraformaldehyde (20 min, RT), stained with 0.1% crystal violet (60 min, RT), and destained with 33% acetic acid (20 min with shaking). The absorbance of the supernatant was then measured at 570 nm using plate reader ( Supplementary Fig. 9 ).
Immunocytochemistry. The hESC were fixed with 4% paraformaldehyde (20 min, RT), permeabilized with 0.1% Triton-X100 in PBS (20 min, RT), and incubated with primary antibodies at 4°C overnight. Primary antibodies included goat polyclonal anti-Oct4 (Santa Cruz Biotechnology, USA) and rabbit monoclonal anti-Nanog (Cell Signaling technology, USA).
Next day, incubations with secondary antibodies conjugated to AlexaFluor488 or AlexaFluor594 (Thermo Fisher Scientific, USA) were carried out at RT for 1 h. Coverslips 28 were mounted in DAPI-containing Mowiol (Sigma-Aldrich, USA). Microscopic analysis was performed using Confocal LSM 700 microscope (Zeiss, Germany; Supplementary Fig. 10 ).
Preparation of hydrogel. Macroporous poly(2-hydroxyethyl methacrylate) (PHEMA) microspheres of narrow particle size distribution were prepared by multi-step swelling polymerization. 43 Briefly, the method is based on 0.7 µm monodisperse polystyrene seeds which are swollen with activating agent (dibutyl phthalate), monomers (2-(methacryloyl)oxyethyl acetate, 2-[(methoxycarbonyl)methoxy]ethyl methacrylate, ethylene dimethacrylate), and porogen (cyclohexyl acetate). After benzoyl peroxide-initiated and (hydroxypropyl)methyl cellulose-stabilized polymerization, hydrolysis, and washing, the resulting PHEMA microspheres were 3 µm in diameter, with a narrow size distribution ( Supplementary Fig. 11 ) and contained 0.5 mmol COOH/g.
In vivo experiment. Animals used in the study of hair promoting activity, 7 weeks old female C57BL/6 mice, were obtained from Laboratory Animal Breeding and Experimental Facility (Masaryk University, Brno, Czech Republic) and maintained on a standard laboratory diet and water as libitum. 17 animals in 3 randomized groups (n=5 or 6) were shaved using depilatory cream (Veet, USA) at 7 weeks of age, at which all hair follicles were synchronized in the quiescence telogen. 44 FGF2, both FGF2-G0 and thermostable variant FGF2-G3 (5 µg per mouse) were dissolved in 0,1% human serum albumin and sorbed into the hydrogel by continuous stirring for 2 hours at RT. The resulted suspension was applied topically on dorsal skin of C57BL/6 mice with subcutaneous injection. Empty hydrogel with no FGF2 was used as a control. Visible hair growth was recorded at days 1, 7, 13, 16 and 20 ( Supplementary Fig.   12 ).
Hair length determination. To examine the effect of FGF2 in hydrogel on hair length, hairs on the proximity of injected site were plucked randomly by forceps at day 21 post application. The average length of the 20 plucked hairs per mouse was measured manually with a micrometer under a stereoscopic microscope and expressed in millimeters.
